help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2006-0414
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/9/4438    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castillo, V.
Right arrow Articles by Arzt, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castillo, V.
Right arrow Articles by Arzt, E.
Endocrinology Vol. 147, No. 9 4438-4444
Copyright © 2006 by The Endocrine Society

Retinoic Acid as a Novel Medical Therapy for Cushing’s Disease in Dogs

Victor Castillo, Damiana Giacomini, Marcelo Páez-Pereda, Johanna Stalla, Marta Labeur, Marily Theodoropoulou, Florian Holsboer, Ashley B. Grossman, Günter K. Stalla and Eduardo Arzt

Unidad de Endocrinología (V.C.), Hospital Escuela, Facultad de Ciencias Veterinarias, and Laboratorio de Fisiología y Biología Molecular (D.G., E.A.), Departamento de Fisiología, Biología Molecular y Celular, Facultad Ciencias Exactas y Naturales, Universidad de Buenos Aires, 1428 Buenos Aires, Argentina; Max-Planck-Institute of Psychiatry (M.P.-P., J.S., M.L., M.T., F.H., G.K.S.) and Affectis Pharmaceuticals (M.P.-P.), 80804 Munich, Germany; Department of Endocrinology (A.B.G.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1A 7BE, United Kingdom; and Instituto de Fisiología, Biología Molecular y Neurociencias-Argentine National Research Council (E.A.), Consejo Nacional de Investigaciones Cientificas y Técnicas, 1428 Buenos Aires, Argentina

Address all correspondence and requests for reprints to: Prof. A. B. Grossman, Department of Endocrinology, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom. E-mail: A.B.Grossman{at}qmul.ac.uk; or Prof. E. Arzt, Laboratorio Fisiología y Biología Molecular, Departimento de Fisiología, Biología Molecular y Celular, FCEN, Universidad de Buenos Aires, Ciudad Universitaria, Pabellon II, 1428 Buenos Aires, Argentina. E-mail: earzt{at}fbmc.fcen.uba.ar.

Cushing’s disease is almost always caused by an ACTH-secreting pituitary tumor, but effective medical therapy is currently limited. Because retinoic acid has been shown to be potentially useful in decreasing corticotroph secretion and proliferation in rodent models, we have studied its action in dogs with Cushing’s disease. A randomized treatment with retinoic acid (n = 22) vs. ketoconazole (n = 20) in dogs with Cushing’s disease was assigned for a period of 180 d. Clinical signs, plasma ACTH and {alpha}-MSH, the cortisol/creatinine urine ratio, and pituitary magnetic resonance imaging were assessed and compared at different time points. We recorded a significant reduction in plasma ACTH and {alpha}-MSH, and also in the cortisol/creatinine urine ratio, of the dogs treated with retinoic acid. Pituitary adenoma size was also significantly reduced at the end of retinoic acid treatment. Survival time and all the clinical signs evaluated showed an improvement in the retinoic-acid-treated dogs. No adverse events or signs of hepatotoxicity were observed, suggesting that the drug is not only effective but also safe. Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype. This study highlights the possibility of using retinoic acid as a novel therapy in the treatment of ACTH-secreting tumors in humans with Cushing’s disease.




This article has been cited by other articles:


Home page
EndocrinologyHome page
C. de Bruin, J. M. Hanson, B. P. Meij, H. S. Kooistra, A. M. Waaijers, P. Uitterlinden, S. W. J. Lamberts, and L. J. Hofland
Expression and Functional Analysis of Dopamine Receptor Subtype 2 and Somatostatin Receptor Subtypes in Canine Cushing's Disease
Endocrinology, September 1, 2008; 149(9): 4357 - 4366.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. M. K. Biller, A. B. Grossman, P. M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A. R. Hermus, L. J. Hofland, et al.
Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2454 - 2462.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Munir, F. Song, P. Ince, S. J. Walters, R. Ross, and J. Newell-Price
Ineffectiveness of Rosiglitazone Therapy in Nelson's Syndrome
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1758 - 1763.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society